Journal article

Protecting Profits Post-Patent Expiry: ACCC v Pfizer, Patents and Competition Law

Arlen Duke, Rhonda Smith

AUSTRALIAN INTELLECTUAL PROPERTY JOURNAL | Thomson Reuters | Published : 2019

Abstract

In the lead up to patent expiry, pharmaceutical companies often engage in strategies designed to delay the production of generic medicines. This article considers whether such conduct is likely to be caught by competition law prohibitions. The article focuses on the recent Federal Court decision in Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd. The court's analysis of the conduct engaged in by Pfizer Australia is interesting in its own right. Further, the judgement provides guidance as to whether or not a firm will be viewed as possessing market power in the period leading up to patent expiry. The judgment also indicates that a firm may escape liability on the bas..

View full abstract